医学
心理干预
心脏病学
儿科
内科学
急诊医学
重症监护医学
精神科
作者
Mads Damkjær,Ester Garne,Maria Loane,Stine Kjær Urhøj,Elisa Ballardini,Clara Cavero‐Carbonell,Alessio Coi,Laura García‐Villodre,Joanne Given,Mika Gissler,Anna Heino,Sue Jordan,Elizabeth Limb,Amanda J. Neville,Anna Pierini,Anke Rißmann,Joachim Tan,Ieuan Scanlon,Joan K. Morris
标识
DOI:10.1161/jaha.122.029871
摘要
Background The purpose of this study was to evaluate the timing of the first cardiac surgery, the number of cardiac surgeries performed, and 30‐day postoperative mortality rate for children with severe congenital heart defects (sCHDs) in their first 5 years of life. Methods and Results This was a population‐based data linkage cohort study linking information from 9 European congenital anomaly registries to vital statistics and hospital databases. Data were extracted for 5693 children with sCHDs born from 1995 to 2004. Subgroup analyses were performed for specific types of sCHD. Children with sCHDs underwent their first surgical intervention at a median age of 3.6 (95% CI, 2.6–4.5) weeks. The timing of the first surgery for most subtypes of sCHD was consistent across Europe. In the first 5 years of life, children with hypoplastic left heart underwent the most cardiac surgeries, with a median of 4.4 (95% CI, 3.1–5.6). The 30‐day postoperative mortality rate in children aged <1 year ranged from 1.1% (95% CI, 0.5%–2.1%) for tetralogy of Fallot to 23% (95% CI, 12%–37%) for Ebstein anomaly. The 30‐day postoperative mortality rate was highest for children undergoing surgery in the first month of life. Overall 5‐year survival for sCHD was <90% for all sCHDs, except transposition of the great arteries, tetralogy of Fallot, and coarctation of the aorta. Conclusions There were no major differences among the 9 regions in the timing, 30‐day postoperative mortality rate, and number of operations performed for sCHD. Despite an overall good prognosis for most congenital heart defects, some lesions were still associated with substantial postoperative death.
科研通智能强力驱动
Strongly Powered by AbleSci AI